Company brochure - Engelhard Arzneimittel

Contents
4 Editorial
6 About us
8 Our core areas of therapy
10 Innovation and cooperation: the key to success
12 Past and future
14 Engelhard worldwide
16 Researching for you – Research & Development
18 Quality from a single source – our production
22 Facts and figures
23 Taking responsibility
24 Overview of products

Oliver Karl Maximilian Engelhard
Richard Mark Engelhard
Dr Rolf Engelhard
Georg Maximilian Engelhard
4

Editorial
Oliver Karl Maximilian Engelhard
We at Engelhard know what sets a really
high-quality medicine apart: a good benefitto-risk
ratio. On the one hand, a medicine
must be effective; on the other, it must be
patient-friendly. This quality awareness is
the basis of our business activities and influences
the questions we ask and decisions we
make in our daily work. It also pervades all
of our internal departments, from Research &
Development to Sales and Production.
We are driven by our vision of being able to
provide individual patients with remedies
geared towards their specific needs, thereby
boosting their long-term health. For the last
140 years, the Engelhard family has been
working to make this vision a reality – and
we will continue to reconcile success and
productivity with an ethical, sustainable approach
to business. After all, our sole aim is
to produce medication that medical specialists
will be able to recommend without hesitation
to patients and that satisfied users will
recommend to their families and friends.
Georg Maximilian Engelhard
Managing a family company entails a unique
responsibility. However, it is not just a question
of preserving the company’s heritage or
core values. Rather, we must harmonise the
old and the new, the traditional and the innovative
– and because we do this to great effect,
we can look ahead to a healthy and modern
future together with our employees.
Richard Mark Engelhard
Our key strength lies in our understanding
of partnership. This can be seen every day in
our dealings with our employees, with pharmacists
and doctors, and with our foreign
partners. Together with these partners, we
have been able to establish our company in
some 90 countries to date and aim to build
on this success in the years to come.
Dr Rolf Engelhard
Without research there can be no progress.
This is why we are especially proud of our
Research & Development department,
which helps to ensure that Engelhard is
always at the cutting edge of innovation.
Thanks to our diverse research cooperations,
we are in a position to share and expand
our know-how strategically. This, in
turn, helps to keep our products innovative
and our patients healthy.
Sincerely,
Oliver Karl Maximilian Engelhard Georg Maximilian Engelhard Richard Mark Engelhard Dr Rolf Engelhard
5

“Engelhard Arzneimittel is characterised by
its exceptional flexibility and offers varied
challenges to its employees, even those who
are new to the sector.”
Lisa Kunzmann
International Regulatory Affairs Manager
“Engelhard Arzneimittel’s
social involvement is worthy of
particular mention.”
Marcel Hoang Van
Customer Service Assistant
About us
“Working relationships based on partnership
are very important here
at Engelhard Arzneimittel.”
Jürgen Kohler
Regional Field Service Director
For 140 years we have been constantly developing
new ideas for improving the health of our customers.
With passion and dedication, we research, develop
and produce high-quality medicines for patients
all over the world. In spite of our company’s
enormous growth and international success, one
important factor has remained unchanged: we
are still an independent family company that believes
in the value of working relationships based
on mutual trust and cooperation.
Tradition and innovation are by no means
mutually exclusive. Quite the opposite in fact:
when the work in question is defined by passion,
tradition and innovation can be said to
be opposite sides of the same coin. Founded
in 1872 by pharmacist Karl Philipp Engelhard,
Engelhard Arzneimittel has developed over
the past 140 years into a modern, international
pharmaceutical company. Today, we employ
some 300 people and still have our sights set
on further growth.
Although our company has developed into a
successful global producer of medicines, we
still see ourselves first and foremost as a family
company founded on trust, mutual respect
and short communication channels. The closeknit
working relationship that we enjoy as a
reliable partner to pharmacies is something
that has not changed since the earliest days.
This close and open communication also influ -
en c es the way we work together with the dif -
fer ent players in the healthcare market: patients,
pharmacists and doctors, distribution
partners and employees, universities and research
institutions.
Our objective is to find the perfect
balance between effectiveness
and tolerability
We aim to develop products that will keep our
customers and their families in the very best
of health. This means establishing the perfect
balance between benefits and risks for all our
medicines. We are one of the few pharmaceutical
companies in Germany to focus on
researching and developing gentle yet effective
medicines for infants, children and young
people – something that we have been doing
6

“I am proud to be able to work
for the Engelhard family.”
Sylwester Baum
Pharmaceutical warehouse employee
“It is important for me to be part of an
ethical company and to work closely
with our partners.”
Deniz Kahraman
Regional Pharma Marketing Coordinator
for many years. Given the minimal side effects
and excellent tolerability of our medicines,
they are also very suitable for older people.
Our product portfolio includes many different
remedies for respiratory tract illnesses, skin
conditions, attention deficit disorders and
digestive problems. The effectiveness of all our
medicines has been scientifically proven. They
are safe to use and have very few side effects. To
ensure that we can always make such a claim,
our products are constantly measured against
the highest international quality standards. As
our products are manufactured internally, we
can monitor all processes continually as well
as enjoying maximum flexibility.
Tried and trusted products such
as Prospan®, Isla Lozenges and
Tyrosur® are synonymous with
high quality
The quality awareness that has characterised
our company for decades is typified by wellestablished
brands such as Prospan®, Isla
Lozenges and Tyrosur®. By researching the
medical properties of ivy, we unlocked the
mechanism of action of alpha-hederin – a
milestone in rational phytotherapy.
All processes involved in our work are governed
by a strong ethical code. This begins
with sourcing sustainable raw materials and is
evident throughout the entire manufacturing
process, right up to the final product. Our aim
is to identify the needs of our patients and to
gear our products to these needs. This means
that, rather than following trends, we believe
in organic working relationships based primarily
on trust.
The success that we have enjoyed for decades
allows us to look to the future with confidence.
We want to continue growing, to expand our
brands and to step up our international activities.
We want to lead our company into a mo d-
ern future – and to retain our all-important independence
in our dealings with our patients,
our partners and our employees.
7

Our core areas of therapy
When Karl Philipp Engelhard developed Iceland
moss lozenges back in 1868, this marked
the beginning of a long-standing success
story for the Engelhard family company. Today,
more than 140 years later, respiratory
tract illnesses remain one of our core areas of
therapy and Isla-Moos® Lozenges are still one
of our best-selling products. These were joined
by new medicines developed by our company,
such as Prospan®, which is used to treat respiratory
tract illnesses. We also expanded our
portfolio to include dermatological preparations
and products for treating attention deficit
disorders and digestive problems.
Respiratory tract illnesses
Did you know that 10,000 litres of air flow through
your respiratory passages every day? The body’s
respiratory organs – the nose, mouth, windpipe,
bronchial tubes and lungs – transport vital oxygen
from the air into our bodies and expel the
used air, which has a high carbon dioxide content.
If the respiratory passages are being attacked, the
versatile remedies from Engelhard Arzneimittel
are at hand to provide relief.
The nose warms and moistens air and filters it
through small hairs at the nasal entrance. Certain
external factors – such as the side effects of
medicines, heated and air-conditioned rooms,
dust and other irritants – can cause the nasal
mucous membranes to dry out. The crust formations
caused by nasal dryness are not only
a nuisance, but can also be very painful. Dry
noses are also more prone to infection.
Nisita® Nasal Ointment and Nasal Spray can
help to moisten nasal mucous membranes
that are dry or under attack. The mucous membranes
of the mouth can also be attacked or
dry for a variety of reasons. The valuable minerals
contained in Nisita® Lozenges increase the
natural production of saliva and help the mucous
membranes of the mouth to regenerate.
Products with chlorhexidine help to combat
bacterial infections of the gums and mucous
membranes of the mouth.
The bronchial tubes can also be attacked by
cold viruses. Particularly during cold and wet
weather, our immune systems may be too
weakened to fend off viruses. Prospan® helps
to loosen coughs and phlegm while soothing
irritated throats at the same time. Iceland moss
is another well-established remedy for ticklish
coughs and hoarse throats: The ingredients
contained in Isla Lozenges coat the mucous
membranes in the throat, thus protecting them
from further attacks.
A sore throat is often the result of a cold, but can
also be attributed to strained vocal cords or irritated
respiratory passages. Trachilid® Sore Throat
Lozenges are an effective remedy against painful
reddening and swelling in the throat. Citramin®
Throat Lozenges provide relief from mild inflammations
of the mucosa of the mouth and throat.
Skin conditions
With a surface area of two square metres, the skin
is both our largest and our most versatile organ.
It defines our appearance, regulates our body’s
warmth and fluid balance, provides immune defence
and allows us to feel and touch things. As
it protects our insides from the outside world, it
is exposed to environmental influences far more
than any other organ. Whenever the skin becomes
imbalanced owing to injuries, irritations or
infections, Engelhard Arzneimittel products can
help to redress the balance.
In everyday life, a fall when playing sports or a
momentary lapse of concentration when chopping
vegetables or working in the garden is all
it takes to damage the skin. Tyrosur®, which is
available as a cooling gel or powder, can be
used for grazes, cuts, scratches, minor burns
and many other superficial skin injuries. Thanks
to its strong antibacterial effects, it provides
reliable treatment for secondarily infected
wounds and helps the skin to heal. Fungi can
also attack both children’s and adults’ skin.
Mykoderm® products – Mykoderm® Healing
Ointment, Mykoderm® Miconazole Cream and
Mykoderm® Mouth Gel – are highly effective in
8

dealing with different fungal infections. When
it comes to treating wounds, Dialon® Zinc Ointment
boosts the skin’s natural regeneration
process. Zinc oxide binds wound secretion
and protects the skin from external influences.
Dialon® Zinc Ointment also helps oozing or
itching wounds to heal. White petroleum jelly
protects the skin from cold or rough weather.
Attention deficit disorders
Concentrating means consciously focusing your
entire attention on one particular activity. It is not
easy to avoid being distracted – particularly for
children who are faced with many new challenges
when they start school. Esprico® is an effective
nutrition therapy used to treat AD(H)D (attention
deficit hyperactivity disorder), learning disorders
and concentration problems.
For most children starting school, it is not just
the lessons themselves that constitute a major
change. There is also the unfamiliar environment
to be considered, not to mention the new
names and faces and the need to sit still for long
periods of time. Children are not born with the
concentration skills that they need in school.
Rather, these are the result of a maturing and
learning process that not every child has completed
by the same stage. Many children have
phases where they find it difficult to concentrate.
Factors such as stress, an un balanced diet
or a lack of exercise can take its toll on a child’s
ability to concentrate. AD(H)D is not a transient
disorder, but tends to last at least six months.
It manifests itself in exceptionally inattentive
and impulsive behaviour, particularly in group
situations, and frequently through inner and/
or visible anxiety. Esprico® contains sea fish oil
with a high omega-3 concentrate and omega-6
fatty acids. It also contains the minerals zinc and
magnesium. Engelhard Arzneimittel developed
Esprico® (in the form of a chewable capsule or
single-dose sachet) based on the latest scientific
research on the nutritional needs of children
aged five upwards who suffer from AD(H)D.
Digestive problems
The human intestine measures some eight metres
in length with a surface area of around 300
square metres. Together with the mouth, throat,
oesophagus and stomach, it works to break down
food intake in order to supply the body with the
nutrients it needs. When our intestines are not
functioning properly and our natural digestion
is disrupted, this soon takes its toll on our wellbeing.
Constipation is a widespread digestive problem,
particularly among older people, and affects
an estimated 20 per cent of the population
on a regular basis. Digestive problems can be
due to many different reasons – lack of exercise,
stress, insufficient roughage or side effects from
certain types of medicines. In the case of infants
and small children, it can also be caused by incorrect
diet, change of living environment and
psychological factors. Anyone experiencing
a change of routine can try to avoid digestive
problems by drinking sufficient liquids, eating
regular small meals with wholegrain products,
fruit and vegetables, and by taking plenty of
exercise. If constipation still occurs, Glycilax®
can help. This contains the active ingredient
glycerol, which softens the intestinal contents,
thus stimulating and facilitating the processes
of normal evacuation. Glycilax®, which is gentle
enough to be used for infants, is available for
both children and adults.
9

Innovation and cooperation:
the key to success
Spotlight on pharmaceutical
SMEs – interview with Managing
Director Richard Mark Engelhard
Today, it is no longer large companies, but rather
SMEs such as Engelhard Arzneimittel and biotechnology
companies, who are largely responsible
for shaping the German pharmaceutical
sector. They form the backbone of this significant
industrial sector, employing over 100,000 people
– and are faced with the many different challenges
that are presented by a changing industry.
We meet these challenges with innovation,
broad-based cooperation and far-sightedness.
Mr Engelhard, what characterises the
German pharmaceutical sector at
present and how do you think it will
develop?
In recent years, competitive pressure on the
market has increased significantly – among
other things – as a result of new laws and discount
schemes. The role of patients has also
changed, given that they are far better informed
than just a few years ago and demand
nothing less than high-quality medicines.
These developments raise the standards expected
of medicine producers such as ourselves.
In future, I believe that price pressure
will remain at a similarly high level. As well as
this, the trend towards self-medication will
continue as health insurance providers struggle
to cover the cost of prescription-only medicines.
Not an easy situation by any means, but
players that have specialised or carved out a
niche for themselves have a good chance of
holding their own on the market.
How significant is the German pharmaceutical
sector by international comparison?
Generally speaking, SMEs still have a very
strong presence in Germany – I am glad to say
that this is also the case in the pharmaceutical
sector. As far as larger companies are concerned,
Germany has dwindled somewhat in
significance as an industrial producer in recent
decades. If you look back to the 1990s, many
large multinationals were still based in Germany
at that time. Owing to a number of factors,
including globalisation and growing political
pressure, Germany has lost some of its relevance
as a production location. Legal conditions
relating to research and low overall funding
for research have also played their part.
How does Engelhard Arzneimittel counter
the trend towards globalisation in the
pharmaceutical sector?
For a start, we are internationalising our own
company as well: Engelhard is now represented
in some 90 countries, giving us a very good
basis to work with. The key to our success is the
excellent working relationship that we enjoy
with our partners in other countries. At Engelhard,
“partnership” is not just an empty buzzword
– it is something that is alive and well in
our everyday work. Another important factor is
our increased inward focus. Engelhard concentrates
on a small but strong product portfolio.
We put our entire heart – and our full concentration
– into everything we do. In this way, we
attain the core competency and the efficiency
that we need to hold our own against other,
often larger companies in highly competitive
markets such as the market for cold remedies.
Where else do you see the strengths of
pharmaceutical SMEs – and Engelhard
Arzneimittel in particular – compared
with large companies?
A key advantage of pharmaceutical SMEs is
their great proximity to the market, i.e. the close
ties they have with patients, doctors and pharmacists.
This allows us to take action quickly
and flexibly at all times. As well as this, SMEs are
frequently very open to external cooperation.
From the very earliest days, it has been part of
Engelhard Arzneimittel’s company philosophy
to learn and benefit from joining forces with
10

other companies and with universities. As it
happens, we have just entered into another
cooperation project with a university. As well
as this, a biotech company approached us
with a view to developing a new medication
together. Working together on equal terms
is very important in this connection. Another
great advantage is that we can cover all bases
– from research and development to production
and sales – ourselves without having
to outsource any functions, something
that appears to be the case more and more
with other companies. Our number one aim
is to adhere to delivery deadlines and quality
standards at all times. As well as this, we retain
our independence, which in turn allows
us to “think sustainably” and gives us plenty
of room to manoeuvre.
Which political changes would
you like to see?
Austerity policies and mandatory discounts
constitute a major challenge for pharmaceutical
SMEs, given that they frequently result
in a lack of funds for research and development.
I hope that we can open another
door here by securing support for research.
Research incentives and grants can make
an important difference – one that would
also help to cement Germany’s status as a
producer of pharmaceuticals. Our strategy
of concentrating on the OTC market turned
out to be a correct and forward-looking one
in view of the “empty coffers” situation with
health insurance providers. This strategy
gives us the room we need to remain close
to patients and to communicate with doctors
and pharmacists.
How do you define innovations and
new developments in pharmaceutics
– and is it possible for pharmaceutical
SMEs to come up with these?
Innovations do not necessarily mean that a
new molecule has to be invented. If an existing
active ingredient is further developed
and, for example, can be administered in a
new, more effective form, I see that as being
an innovation as well. If a tablet is smaller
and therefore easier to swallow, thus increasing
compliance, then I would consider this to
be an important benefit for patients. This example
shows that there is plenty of potential
for SMEs to offer innovations. For example,
in the case of Prospan® we constantly looked
for ways of improving the product and continue
to do so to this day. Close contact with
and feedback from pharmacists and patients
are extremely important in this regard. For
instance, an important innovation was how
we transformed the very bitter-tasting dried
ivy extract into a palatable liquid. The same
goes for the practical single-dose sachets for
adults who are on the move.
What do you think the future holds for
Engelhard Arzneimittel and pharmaceutical
SMEs in general?
I believe that pharmaceutical SMEs in Germany
will continue to be a strong force.
There are good prospects for players that
are well positioned and that know their core
competencies. We are working constantly to
make our products even more effective and
patient-friendly. In the future, we will continue
to work to the same high standards
and to maintain our close partnership with
pharmacies, doctors and foreign partners. I
look to the future with optimism.
Did you know…?
There are 903 pharmaceutical
companies in Germany. In 2010,
the pharmaceutical sector in
Germany manufactured pharmaceutical
products valued at
€26.9 billion.
In 2010, a total of 103,208 people
were employed by companies
producing pharmaceutical
products. In Germany, the pharmaceutical
industry invested
around €5.5 billion in research
and development in 2010.
Source: Pharmaceutical data 2011, published
by the German Pharmaceutical Industry
Association (BPI)
11

Past and future
Rosen-Apotheke opens
Karl Philipp Engelhard’s entrepreneurial
career begins in 1861 when his
father Georg Heinrich Engelhard hands
over to him the Rosen-Apotheke, a
pharmacy he had opened back in 1826.
Karl Engelhard sells the pharmacy in
1901 due to time constraints but remains
loyal to the profession until the
end of his life. This commitment earns
him an honorary membership of the
Deutscher Apothekerverein (German
Pharmacists’ Association) in 1922.
Inception of the
pharmaceutical plant
By this time, pharmacist Karl Philipp
Engelhard has already ten years of
successful entrepreneurship under his
belt. His excellent business skills and
keen sense for product development
enable him to sell his products beyond
the local community, beyond the limits
of the city of Frankfurt and even beyond
the German border.
1872
Engelhard builds a plant
in the north-east of Frankfurt
Rising sales lead the company to move
to a new plant of its own. Karl Philipp
Engelhard invests in the right place at
the right time. Building a new plant
proves to be a milestone in the creation
of the company’s own business
model and in establishing business
strategies that still shape the company
today.
1891
The second generation:
both sons join the company
Karl Philipp Engelhard can retire safe
in the knowledge that his hard work
and high standards have borne fruit.
And that his company is in the capable
hands of two of his four children. Paul
and Max Engelhard lead the company
as of 1919, continuing their father’s
successful work. A family-run company
is born.
1919
Rebuilding the company –
a joint effort
The company is rebuilt in record time
after World War II. The close relationship
between management and employees
is instrumental in rebuilding
the largely destroyed plant swiftly,
helping the company’s main products
to return to production by as early as
1948.
1945
1826
Isla Moos Paste
Karl Philipp Engelhard develops a
recipe for a paste made of Iceland
moss that relieves sore throats and has
a soothing effect on the vocal cords.
Over 140 years later, Isla-Moos® is one
of Engelhard’s best-selling products,
a success story that remains unparalleled
today.
First gas engine
The orders are so numerous that they
can no longer be prepared by hand.
Karl Philipp Engelhard responds
quickly to the growth in orders by automating
the process, thus paving the
pharmacy’s way to expansion.
1888
Dialon and custom
packaging
A unique business model is created in
the 1890s when Engelhard is one of
the first companies to produce custom
packaging. The company enables
pharmacists to customise industrial
products by printing the name of their
pharmacy on the packaging. Engelhard
also introduces Dialon powder, a
child care and skin care product that
evolves over the next ten years into
Engelhard Arzneimittel’s well-known
product.
1890s
In-house print shop,
groundbreaking advertising
campaigns for Dialon
The two new managing directors, Paul
and Max Engelhard, put the business
skills they inherited from their father to
good use: Dialon is systematically expanded.
An in-house print shop starts
printing the custom designs on the
packaging, also producing impressive
advertising campaigns for Dialon.
1923
The third generation
Karl and Max Engelhard are the third
generation of managing directors at
the helm of the company. They are
forced to find their feet quickly in order
to cope with the challenges of World
War II.
1939
1868
1826 1868
1872 1888 1890s 1891 1919 1923 1939 1945
12

Penicillin
Relocation to Frankfurt
The third generation of managing
directors is a credit to the name Engelhard.
Swiftly assessing the needs of the
population at the end of World War II,
Karl and Max Engelhard add penicillin
to their product range, making Engelhard
one of the first pharmaceutical
companies in Germany to process it.
Other antibiotics gradually follow as a
result of Engelhard’s ongoing research.
1949
Tyrosur®
Tyrosur®, with the active ingredient
Tyrothricin, is another product developed
in-house by Engelhard Arzneimittel.
Today, the product is still a successful
self-treatment remedy for wounds.
1959
Preparing and expanding
for internationalisation
From 1980 onwards, Engelhard follows
up on the first international successes
of the 1930s. The international expansion
activities focus initially on a small
number of countries but soon branch
out further afield. This new chapter in
the Engelhard success story is still being
written today.
1980
Now over a century old, the original
plant is no longer able to meet the requirements
of the production processes
and the orders are too much for the
machines to handle. A building already
owned by the company in the northeast
of Frankfurt is converted and
equipped with state-of-the-art technology
and production equipment.
1996 onwards
140 years of
Engelhard Arzneimittel
Engelhard Arzneimittel celebrates
its 140th anniversary in 2012. The independent
family business employs
some 300 permanent employees and
its products are sold in around 90
countries around the world.
2012
Fifth generation
Prospan®
Prospan® Cough Drops are already the
second new product to be launched
successfully since the war. During the
economic recovery, the ivy cough
drops turn out to be a real asset for
the company’s herbal medicine business.
The cough medicine sold under
the brand name Prospan® quickly becomes
the company’s highest-selling
and most-promoted product. This lays
the foundation for ongoing research
to further develop and establish the
Prospan® product line.
Fourth generation
The great-grandchildren of the company’s
founder, Dr Rolf Engelhard, Karl Michael
Engelhard and Georg Maximilian
Engelhard, join the family business one
after another. Together, they successfully
steer the company through the
difficult years of the 1970s in Germany,
enabling it to emerge from the recession
even stronger. The fourth generation
modernises the company effectively,
without losing sight of tradition.
Prospan® Cough Syrup
Prospan® Cough Syrup, the product
of years of research by Engelhard Arzneimittel,
exceeds all expectations
when launched. The syrup combines
the effective active ingredient derived
from ivy leaves and, being free of alcohol
and sugar, the requirements of a
children’s medication. Its dosage form
is a milestone in the expansion of the
company’s domestic business and export
markets.
The company is some 130 years old
when the fifth generation of managing
directors takes over at the helm.
Oliver Karl Maximilian and Richard
Mark Engelhard are also committed
to maintaining the values of the
company’s founder who defined entrepreneurship
as a balance between
tradition and innovation, preferred
steady growth to hasty actions, and
understood early in his career just how
important it is to establish and manage
brands.
2001
Breakthrough in
phytotherapy research
Engelhard Arzneimittel is a pioneer
in conducting basic research into the
medicinal properties of ivy, thus unlocking
the mechanism of action of
alpha-hederin – a milestone in rational
phytotherapy.
2003
1950
1971 onwards
1991
1949 1950
1959 1971 onwards
1980
1991 1996 onwards
2001
2003
2012
13

Engelhard worldwide
Mauricio Aravena,
Director of Field Sales and International Division
Engelhard Arzneimittel recognised at a very early stage that its prod -
ucts also had great potential for the international market. From
small beginnings, the company’s export business flourished: today,
its products are sold in some 90 countries and the company works
closely together with independent distribution partners on all
continents.
All over the world, Engelhard products are a byword for
quality and reliability. However, strong products alone are
not enough to be a successful international player. The
company draws great strength from the close working relationship
that it enjoys with all of its partners worldwide. As
Mauricio Aravena, Director of Field Sales and International
Division, stresses: “This is the key to our success.” Engelhard
Arzneimittel’s international activities are also founded on
close long-term partnerships, mutual trust, and professional
working relationships on friendly, equal terms.
Prospan® – the international top seller
Just as it is in Germany, Prospan® is one of the company’s bestselling
products on the international market – in fact, in terms
of sales revenue and unit sales, it is the best-selling herbal cough
syrup in the world. Prospan® is the market leader in over 40 countries
and even has a double-digit market share in most. No mean feat,
especially given that the market in most countries was initially dominated
by synthetic products. Mauricio Aravena: “Positioning a purely herbal
product in such a market environment was quite a challenge.” However, once
the product gained a foothold in the market, it soon enjoyed strong growth.
14

The success established Prospan® as something of a pioneer, paving the way
for herbal medicines – both for Engelhard Arzneimittel and for other producers
of phytopharmaceuticals, who took advantage of this shift in the
market and continue to do so.
International growth for the remaining
product range
Other Engelhard Arzneimittel products – such as Isla preparations
or Trachisan® – have also secured leading positions
on foreign markets. As well as this, the company is being
spurred on by the double-digit growth that it has achieved
in recent years. By increasing its brand development, also
including further products from the range, the company
is gradually expanding its existing structures and moving
into new markets. At present, the company’s export markets
are mainly in Central and Eastern Europe, the Middle
East and Latin America. However, it also plans to step up
and expand its activities in Asia, Africa and Western Europe.
The scientific basis of Engelhard products gives all distribution
partners a sound basis for establishing themselves on
their respective markets. And in order to maximise success,
the company provides its partners with well-rounded marketing
solutions to boost their distribution activities.
15

Researching for you –
Research & Development
Patricia Röttger-Lüer,
Approvals Director
“We want to be fast, creative
and flexible. And to do this
we need to be able to see the
bigger picture all the time.”
The best way for a company to ensure a competitive
and technological edge is to develop its
know-how itself. Engelhard Arzneimittel’s Research
& Development department epitomises
the company’s reputation for innovation and the
high quality of its products.
Medical progress is unthinkable without constant
research and development in the field of
medicines. This ties in perfectly with Engelhard
Arzneimittel’s aims of finding new approaches
for innovative medicines and constantly enhancing
its existing products. Top priority is
given to the development of effective yet tolerable
medicines, with minimum side effects.
These goals define the everyday work of the
highly qualified specialists in our Research &
Development department.
It takes a long time for an initial idea to become
a new active ingredient with full approval.
Every day, we oversee numerous studies that
verify the effectiveness and tolerability of our
medicines. Needless to say, the health and
well-being of our customers are always the
primary focus of everything we do.
Combining the best of old
and new
Innovators must remain on the ball and be capable
of thinking in many different directions.
This is why our research and development work
consists largely of combining new ideas with
established solutions. As well as conducting
fundamental research in well-known areas of
therapy, Engelhard Arzneimittel explores new
ground, researching both established and unexplored
substances. This wide spectrum allows
us to continually optimise our existing product
portfolio while discovering new trends at the
same time. The most important requirement
in this regard is that we rigidly adhere to ethical
principles and the highest quality standards
– only in this way can research be completely
objective.
By safeguarding quality, and researching the
active ingredient from ivy leaves that is used in
its Prospan® Cough Syrup, Engelhard succeeded
in raising the bar for rational phytotherapy
and demonstrating its effectiveness in treating
respiratory tract illnesses – a milestone
16

in plant-based medicine research. Prospan®
aside, Engelhard focuses primarily on products
for treating respiratory and dermatological
conditions, mainly pharmacy-only preparations.
In addition to medicines, Engelhard
Arzneimittel researches and develops other
medical products, cosmetics and dietary foods
for specific medical purposes.
Engelhard is also one of the few German companies
to research the specific needs of children
and infants: something it has been doing
for many years. As well as this, the company
focuses much of its attention on developing
gentle, tolerable medicines for older people,
who often suffer from a number of different
conditions at the same time. For these
and other patients, the aim is to find patientfriendly
solutions that meet people’s individual
needs.
Synergies through research
cooperations
New momentum and new ideas are the lifeblood
of product development. This is why
our Research & Development department
works closely together with other internal
departments such as Production and Sales.
However, cooperations with external partners
also play a decisive role in everyday work. For
many years, Engelhard Arzneimittel has drawn
on the experience and expertise of scientists,
universities and institutions. This is because
interacting with specialists provides the vision
that is necessary for developing innovative
perspectives. Joining forces with outstanding
researchers from all over Germany allows us to
leverage many different synergies.
In this way, Engelhard Arzneimittel is also
ideally positioned for the future – there is a
growing need on the market for its special
brand of needs-oriented medicine. As well as
this, the concept of preventative medical care
is increasing in significance. Today, Engelhard
Arzneimittel is already exploring nutritional
and immunological correlations in order to
help prevent illnesses, and to be in a position
to offer consumers patient-friendly medicine
that is tailored to their individual needs.
17

Quality from a single source –
our production
Arranged in tightly packed rows, the small brown glass bottles move
in a jerking motion across the production line. With tireless precision,
the filling nozzle moves up and down, injecting exactly the
same amount of liquid into every bottle. Quick as a flash, a
screw cap is placed around the opening. Under the watchful
eyes and quick hands of a production line worker,
the bottles make their way across the production line
where, in a matter of seconds, they are made instantly
recognisable with a green label featuring
the Prospan® ivy leaf. At our production location
at Niederdorfelden, Engelhard products – including
Prospan® – are manufactured in accordance
with the highest quality standards.
It is a long journey from the ivy leaf to the
finished product on the pharmacy shelf;
one that calls for detailed logistical planning,
extensive quality controls and the
expertise of many in-house specialists.
The overriding commitment to delivering
nothing less than top quality defines
every step of the production process.
Every year, an enormous volume
of products leaves our production facilities.
Enough tablets, in fact, to build
a road from Frankfurt to Barcelona and
enough Prospan® Cough Syrup to fill six
swimming pools!
Dr Oliver Schmidt, Pharmaceutical Director
at Engelhard, notes: “There are many
important aspects to take into account
when producing high-quality medicines.
But one is absolutely crucial: a quality philosophy
and policy must be firmly anchored in
the company and put into practice by each and
every one of its employees.” Based on this quality
philosophy, Engelhard developed a comprehensive
quality management system which ensures that the
processes are transparent and that the facilities and
equipment are suitable for producing medicines. One aspect
is of particular importance for Dr Schmidt: even if a system
is already well developed, the processes are nonetheless
subjected to critical examination on a regular basis. As he himself
explains: “In order to continue improving all the time, we can ask ourselves
what these processes really offer us and how we can make them
even better.”
18

Extensive controls before sourcing
raw materials
The production process begins even before the raw materials
are sourced. Many processes and controls are
required in advance. For instance, it must be ascertained
whether the suppliers are qualified to manufacture
the product in question. Different raw materials
are delivered every day and these must
first be examined thoroughly. Following this,
the raw materials are put into storage until
such time as the Production Planning and
Sales departments schedule the production
of a medication.
The next stage involves preparing for the
production process. Here, employees allocate
all the required materials to the
planned production batches, check
the volumes required and verify once
again that all raw materials have been
tested. Materials that have not been
checked completely are automatically
blocked, thus providing an additional
control instance. After the batch has
been opened a transport order is generated
for the warehouse, from where
all required materials are brought to the
production area. Here, the raw materials
are inspected once again and weighed by
two employees.
Dr Oliver Schmidt firmly believes that it is a
key advantage to have all production under
one roof, so to speak: “Having our entire knowhow
in one place creates absolute transparency.
It also means that we can exert an influence directly
and flexibly and can guarantee maximum security.
As well as this, it makes a difference to our employees
whether the products are manufactured in-house or
whether they are outsourced from an external location.”
19

Separated after weighing
At Engelhard, medicine is produced in solid,
semi-solid and liquid form. This means that,
after being weighed, the raw materials are
separated depending on whether they are to
be granulated and made into tablets or used to
produce ointments or syrups. Liquid and semisolid
remedies are created by mixing together
and stirring individual components. Three
giant vats with a volume of 5,000 litres each are
used for producing Prospan® and other liquid
medicines.
The process used for producing tablets is somewhat
more complex. First of all, the intermediate
product, i.e. granulate, is created by mixing
a number of fixed ingredients together. Next,
the granulate absorbs the dissolved ingredients
and liquid components and is pressed into
tablet form. After this, the tablets are ready to
be packaged.
20

Manufacturing Esprico®
is especially complex
In the case of Prospan® Cough Syrup, for
instance, around two weeks should be planned
from the beginning of production until the final
products have been approved for sale. Over the
course of production, around 25 employees will
have worked on each product. The different
medicines vary in complexity. As Dr Oliver
Schmidt explains: “At the moment, Esprico® is
the product that involves the most work. Due
to the omega-3 and omega-6 fatty acids from
fish oil, it is extremely sensitive to oxygen and
light. Because of this, we must exercise the utmost
care and work under oxygen-free conditions
from the outset.” It is time and effort well
invested: in spite of the unpalatable fish oil that
it contains, the suspension has a pleasant, fruity
taste.
Only when a sample of the final product has
been given the all-clear by the laboratory can
the packaging process begin. This is also an extremely
complex process because the products
are exported to almost 90 countries, almost all
of which have their own special packaging.
Samples are taken once again to check if that
information and packaging materials are correct.
Following this, the samples are submitted
to quality control for a final check. When the allclear
is given here, the finished products can be
sent to the dispatch department – from which
they are then sent to all corners of the world.
A number of checks – known as “in-process
controls” – are also performed during production.
For instance, when manufacturing tablets,
the mass, diameter and hardness of the tablets
are checked every half-hour in order to ensure
consistently high quality.
21

Facts and figures
Profile
Engelhard Arzneimittel is a medium-sized
research-based pharmaceutical company located
in the Rhine-Main region of Germany.
Founded in 1872 by pharmacist Karl Philipp
Engelhard, the family company now has 140
years of experience under its belt.
The product range consists, above all, of
remedies for respiratory and dermatological
conditions, including established phytopharmaceuticals.
The company’s products have established
themselves among the market leaders
both in Germany and abroad.
At present, 304 people are employed in the
production of innovative, high-quality medicines.
Company founded on
31 October 1872
Location
Niederdorfelden, Germany
Areas of therapy
Respiratory tract illnesses, skin conditions,
attention deficit disorders, digestive problems
Portfolio
Medicines, medical products, cosmetics,
dietary foods for special medical purposes
Managing Directors
Georg Maximilian Engelhard
Oliver Karl Maximilian Engelhard
Richard Mark Engelhard
Dr Rolf Engelhard
Brands/products
Prospan®, Isla-Moos®, Isla-Cassis®, Isla-Mint®,
Isla-Ginger®, Tyrosur®, Trachilid®/Trachisan®
Esprico®, Nisita®, Mykoderm®, Glycilax®,
Citramin®, Chlorhexidine preparations, Zinc
Ointment, Dialon®, White Petroleum Jelly
Total sales 2011
Approximately €80 million (+9%)
Number of employees
304
Of which trainees
10
Apprenticeships available
Industrial manager, pharmaceutical technician
Bachelor of Arts – Industrial (B.A.)
Number of export countries
89
Quality management and certification
GMP (Good Manufacturing Practice)
Certificate for ISO 9001 and 13485 standards
Information last updated
August 2012
22

Source: Plan
Taking responsibility
Ever since its earliest days, Engelhard Arzneimittel
has committed itself to helping good causes, supporting
both large-scale initiatives and small local
organisations. Responsibility is part of our corporate
culture – both at regional and international
level.
At Engelhard Arzneimittel, our own success
makes us all the more determined to lend a
helping hand to those who are less fortunate.
Early on in the company’s history, its management
recognised that commercial success
entailed a high level of responsibility, not just
towards employees, customers and partners,
but also towards society and the environment.
Because of this, social commitment has been
firmly rooted in Engelhard Arzneimittel’s company
philosophy from the outset.
Engelhard Arzneimittel has committed itself
to helping many different local, national and
international projects. The company does not
just put its weight behind large, high-profile
projects – it has also worked together with
small, local initiatives for years.
Much of the company’s charitable efforts are in
aid of Plan, an international children’s charity
that runs a “Sponsor a Child” programme. This
organisation works to protect children and
their rights in developing countries in Africa,
Asia and Latin America. It oversees different
projects with a view to bringing about a sustainable
improvement in the living conditions
of children, their families and their communities.
The organisation’s work is independent of
any political, state or church involvement.
Engelhard Arzneimittel has been supporting
this outstanding work since 2010 by sponsoring
almost 40 children, with many more
planned for the future. This project also benefits
from Engelhard’s close-knit working relationship
with foreign companies and both employees
and partners from all over the world
work together to secure sponsorship for as
many children as possible.
Besides its involvement in Plan, Engelhard
Arzneimittel has given valuable assistance
to smaller projects for years. In doing so, the
company aims, above all, to encourage team
and community spirit in a broad spectrum of
social spheres. These include sports teams,
schools and the English Theatre in Frankfurt
am Main. In future, Engelhard aims to continue
supporting these initiatives at local level, thus
allowing it to give something back to the
region.
23

Overview of products*
• An end to tiresome coughs.
Prospan® provides relief. Effective – fast – plant-based
• Relief for sore throats
• Fast and antibacterial treatment for wounds
• Fast relief for sore throats
• Effective nutrition therapy for treating AD(H)D,
learning disorders and concentration problems
• Moisture for nose and mouth
• Mycosis treatment from head to toe
• Digestive problems? Why not try Glycilax®, the gentle laxative?
• For mild inflammations of the mucosa of the mouth and throat
• For treating bacterial infections of the gums and mucous
membranes of the mouth
• For treating wounds
• For protecting and caring for stressed skin
24

*
Mandatory information
Chlorhexidine digluconate ready-to-use solution 0.2% For use in the mouth.
Chlorhexidine digluconate solution 2% Concentrate for producing a solution for use in the mouth. Used for: Temporarily reducing germ count in the oral
cavity; aiding the healing process following periodontal surgery. As a temporary adjuvant therapy for mechanical cleaning, in the case of bacterial infections
in the gums and mucous membranes of the mouth and in the case of limited ability to maintain oral hygiene measures. Warning: Chlorhexidine
digluconate ready-to-use solution 0.2% contains 7.9% alcohol. For information on risks and side effects please read the package insert and consult your
doctor or pharmacist.
Glycilax® for Adults; Glycilax® for Children Active ingredient: Glycerol 85% Used for: Constipation and painful stool evacuation. For information on risks and
side effects please read the package insert and consult your doctor or pharmacist.
Mykoderm® Healing Ointment Active ingredients: Nystatin, zinc oxide Used for: Yeast infections in the skin, which can manifest themselves, for example,
as nappy rash in the natural body folds such as the groin area. For information on risks and side effects please read the package insert and consult your
doctor or pharmacist.
Mykoderm® Miconazole Cream Active ingredient: Miconazole nitrate Used for: Interdigital mycoses, mycoses of the skin and skin folds, superficial
candidiasis. Warning: Contains benzoic acid. For information on risks and side effects please read the package insert and consult your doctor or pharmacist.
Mykoderm® Mouth Gel Active ingredient: Miconazole Used for: Treating yeast infections of the mucous membranes of the mouth (oral thrush). For information
on risks and side effects please read the package insert and consult your doctor or pharmacist.
Prospan® Cough Syrup, liquid; Prospan® Cough Liquid, liquid; Prospan® Effervescent Cough Tablets; Prospan® Cough Drops, liquid Active ingredient: Dried ivy
extract Used for: Treating the symptoms of chronic inflammatory bronchial diseases; treating acute inflammations of the respiratory passages accompanied
by coughing. Note: A doctor should be consulted without delay if symptoms persist or if the patient experiences shortness of breath, fever or
discharge of pus or blood. Warning: Prospan® Effervescent Cough Tablets contain lactose and sodium compounds. Prospan® Cough Drops contain 47%
alcohol. For information on risks and side effects please read the package insert and consult your doctor or pharmacist.
Prospan® Cough Pastilles Active ingredient: Dried ivy extract Used for: Treating the symptoms of chronic inflammatory bronchial diseases; treating cold
symptoms affecting the respiratory passages. For information on risks and side effects please read the package insert and consult your doctor or pharmacist.
Trachilid® Sore Throat Lozenges Active ingredient: Lidocaine hydrochloride 1 H 2
O Used for: Short-term local treatment of sore throats with non-purulent
infections. For information on risks and side effects please read the package insert and consult your doctor or pharmacist.
Tyrosur® Gel , Tyrosur® Powder Active ingredient: Tyrothricin Used for: Alleviating small, superficial wounds with minimal weeping and with bacterial superinfection
with tyrothricin-sensitive pathogens, e.g. tears, scratches and abrasions. Warning: Tyrosur® Gel contains propylene glycol. For information on risks
and side effects please read the package insert and consult your doctor or pharmacist.
Dialon® Zinc Ointment Active ingredient: Zinc oxide Used for: Assisting wound healing, including weeping or itching wounds, cracked skin; for covering
wounded areas of skin. Warning: Contains lanolin alcohols and cetearyl alcohol. For information on risks and side effects please read the package insert
and consult your doctor or pharmacist.
Information last updated
August 2012
25

Publishing details
Published by
Engelhard Arzneimittel GmbH & Co. KG
Herzbergstraße 3
61138 Niederdorfelden, Germany
Tel.: + 49 6101 539-300
Fax: + 49 6101 539-315
www.engelhard.de
email: info@engelhard.de
Editing and design
art tempi communications gmbh,
Cologne
www.art-tempi.de
Production
Heinendruck GmbH, Düsseldorf
www.heinendruck.de
© Engelhard Arzneimittel GmbH & Co. KG,
September 2012